Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $9.1200 (-8.06%) ($9.0800 - $10.0000) on Tue. Feb. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.7% (three month average) | RSI | 48 | Latest Price | $9.1200(-8.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -2% a day on average for past five trading days. | Weekly Trend | AUTL advances 1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) DRIV(16%) EWI(15%) IFRA(15%) XLB(15%) BOTZ(14%) | Factors Impacting AUTL price | AUTL will decline at least -2.35% in a week (0% probabilities). VXX(-9%) VIXM(-8%) TLT(-5%) SHY(-2%) BWX(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.35% (StdDev 4.7%) | Hourly BBV | 0 () | Intraday Trend | -8.1% | | | |
|
Resistance Level | $10.07 | 5 Day Moving Average | $10.08(-9.52%) | 10 Day Moving Average | $10.23(-10.85%) | 20 Day Moving Average | $10.07(-9.43%) | To recent high | -44% | To recent low | 0% | Market Cap | $477m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |